Table 6.
Expression levels of 7 common priority 1 proteins with significant (q < 0.05) differential expression identified in both pig and human serum proteomics studies
| Pig Serum Proteomics Study |
Human Serum Proteomics Study |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean Protein Intensity ± SE (log2)* |
Mean Protein Intensity ± SE (log2)* |
|||||||||||
| Annotation | Maximum Fold Change | Minimum q value | Control Chow Group | Atherogenic Diet Group | M-Ath Diet Group | Annotation | Maximum Fold Change | Minimum q value | Control | Simple Steatosis | NASH | NASH + Advanced Fibrosis |
| Apolipoprotein C-III | 2.20707799 | 0.03941731 | 13.89 ± 0.23 | 14.61 ± 0.28 | 15.03 ± 0.23† | Apolipoprotein C3 | 1.19 | 0.0477 | 14.67 ± 0.07 | 14.54 ± 0.06 | 14.64 ± 0.06 | 14.43 ± 0.06† |
| Orosomucoid 1 | 2.10644948 | 0.00595803 | 14.65 ± 0.12 | 15.73 ± 0.14† | 15.43 ± 0.12† | α-1-acid glycoprotein 1 | 1.40 | 0.02348 | 15.05 ± 0.13 | 15.35 ± 0.10 | 15.21 ± 0.10 | 14.87 ± 0.11‡ |
| Apolipoprotein B | 1.82428754 | 0.0018515 | 13.17 ± 0.10 | 13.55 ± 0.12 | 14.04 ± 0.10† | Apolipoprotein B100 | 1.19 | 0.04079 | 15.06 ± 0.07 | 15.21 ± 0.06 | 15.31 ± 0.06† | 15.23 ± 0.06 |
| Serum amyloid P component | 1.63619691 | 0.00673285 | 13.75 ± 0.11 | 13.71 ± 0.13 | 13.04 ± 0.11†‡ | Serum amyloid P component | 1.36 | 0.000000 | 15.85 ± 0.05 | 15.69 ± 0.04 | 15.61 ± 0.04† | 15.40 ± 0.04†‡§ |
| Transthyretin | 1.48109011 | 0.00242107 | 15.75 ± 0.07 | 15.24 ± 0.08† | 15.18 ± 0.07† | Transthyretin | 1.29 | 0.00029 | 15.91 ± 0.06 | 15.86 ± 0.05 | 15.75 ± 0.05 | 15.55 ± 0.05†‡ |
| Paraoxonase 1 | 1.39969355 | 0.00411286 | 14.09 ± 0.05 | 14.35 ± 0.06 | 13.87 ± 0.05‡ | Paraoxonase 1 | 1.58 | 0.000000 | 14.29 ± 0.05 | 13.68 ± 0.04† | 13.63 ± 0.04† | 13.64 ± 0.04† |
| Similar to α-2-macroglobulin precursor | 1.37850584 | 0.02801592 | 14.50 ± 0.07 | 14.39 ± 0.08 | 14.85 ± 0.07†‡ | α-2-macroglobulin | 1.35 | 0.00548 | 14.43 ± 0.10 | 14.45 ± 0.08 | 14.57 ± 0.08 | 14.86 ± 0.08†‡ |
*log2 scale: a difference of one unit is equivalent to a twofold change. †q < 0.05 vs. control chow group; ‡q < 0.05 vs. atherogenic diet group for the pig study. †q < 0.05 vs. control; ‡q < 0.05 vs. simple steatosis; §q < 0.05 vs. nonalcoholic steatohepatitis (NASH) for the human study. For the human study, group sizes were as follows: control (n = 16), simple steatosis (n = 24), NASH (n = 23), NASH + advanced fibrosis (n = 22).